SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: eico20 who wrote (1309)6/17/2015 4:00:59 PM
From: mokelumne river  Read Replies (1) of 2026
 
Let's use MI's royalty, say $1.50 per unit to keep it simple. Assume (pick a number) that 3 million units are sold in the next 12 months. That raises $4.5M. Not bad. Just for fun, double that and you get $9M. Much better.

However, at the end of the day, that is not even a down payment on the cost of a PIII for Fispemifene. And $9M would not cover 12 months of normal operating expenses much less clinical trial costs. We would have to get King Kong deals on Femprox and new Vitaros licenses and RayVa licenses and I don't see that in the cards, at least in terms of huge upfront cash.

So the big picture for me is the maneuvering that will take place in six months assuming RPRX's drug is approved in the fall. I am assuming that Denner will lead that discussion.

Oh, and addressing our cash situation can't wait until the fall unless we get some infusion from deals.

That is my $.02.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News